"Is It Psychosis or Schizophrenia?"
William K. Warren, Jr. Frontiers in Neuroscience Lecture
Laureate Psychiatric Clinic and Hospital Conference Center
11:00 am - 11:45 am Registration and Lunch, lunch stops being served at 11:45 - no exceptions
12:00 pm - 1:00 pm Program
Dr. Tamminga holds the Lou and Ellen McGinley Distinguished Chair and the McKenzie Chair in Psychiatry at the University of Texas Southwestern Medical School; she is the Chairman of the Department of Psychiatry and the Chief of the Translational Neuroscience Division in Schizophrenia at UTSW. She received her M.D. degree from Vanderbilt University and completed residency training in psychiatry at the University of Chicago. She served on the University of Chicago faculty from 1975 to 1979 and moved to the NINDS for training in Neurology in 1978. After joining the faculty at the University of Maryland Medical School in 1979, she practiced research, clinical care and teaching there until joining the faculty at UT Southwestern Medical School in 2003.
Dr Tamminga is currently a member of NIMH’s National Advisory Board and has served on the Board of Scientific Counselors of the National Institute of Mental Health and the National Institute of Drug Abuse, as Council member and President of the American College of Neuropsychopharmacology, as a Member and Chair of the Psychopharmacological Drugs Advisory Committee of the FDA as well as consultant for the Orphan Products Development Review Group, FDA. She is a member of the Advisory Board of the Brain and Behavioral Research Foundation (NARSAD). She is currently the Deputy Editor of the American Journal of Psychiatry and on the editorial board of several other journals in the field. Dr Tamminga was elected to the Institute of Medicine of the National Academies of Sciences in 1998 and has served on several IOM committees in that capacity.
The goal of Dr. Tamminga’s research is to examine and understand the mechanisms underlying schizophrenia, especially its most prominent symptoms, psychosis and memory dysfunction, in order to build rational treatments for the illness. She evaluates the function of the living human brain in individuals with and without schizophrenia, using brain imaging techniques. Then, building on this knowledge, she uses human postmortem brain tissue to translate the functional alterations from the living human patient into molecular observations of the illness. Her ultimate goal is to base novel pharmacologies for psychosis and memory dysfunction on these observations and to use the altered in vivo imaging and postmortem molecular changes as biomarkers and targets for identifying animal models of disease and novel active pharmaceuticals.
Learning objectives:
1. Review criteria for conventional psychosis diagnosis
2. Review biomarkers for psychosis presentations
3. Consider relationships between clinical and biomarkers characteristics of psychosis.
For Physicians: CME credit will be given.
For Psychologists: The Oklahoma State Board of Examiners of Psychologists, the American Psychological Association and the Oklahoma Psychological Association recognizes AMA PRA Category 1 credit™.
For Social Workers: This event has been approved by the Oklahoma State Board of Licensed Social Workers for 1 hour Category 1Clinical. (CEP Number - 20150007)
For LPCs and LMFTs: An application has been made to the State Board of Behavioral Health Licensure (BBHL) for 1 hour of CE.
For CADCs and LADCs: Laureate Psychiatric Clinic and Hospital, Tulsa, Oklahoma, is accredited as a provider of continuing chemical dependency education by the State of Oklahoma - Board of Licensed Alcohol and Drug Counselors for 1 hour of CE.
REGISTER TO ATTEND!
William K. Warren, Jr. Frontiers in Neuroscience Lecture
Laureate Psychiatric Clinic and Hospital Conference Center
11:00 am - 11:45 am Registration and Lunch, lunch stops being served at 11:45 - no exceptions
12:00 pm - 1:00 pm Program
Dr. Tamminga holds the Lou and Ellen McGinley Distinguished Chair and the McKenzie Chair in Psychiatry at the University of Texas Southwestern Medical School; she is the Chairman of the Department of Psychiatry and the Chief of the Translational Neuroscience Division in Schizophrenia at UTSW. She received her M.D. degree from Vanderbilt University and completed residency training in psychiatry at the University of Chicago. She served on the University of Chicago faculty from 1975 to 1979 and moved to the NINDS for training in Neurology in 1978. After joining the faculty at the University of Maryland Medical School in 1979, she practiced research, clinical care and teaching there until joining the faculty at UT Southwestern Medical School in 2003.
Dr Tamminga is currently a member of NIMH’s National Advisory Board and has served on the Board of Scientific Counselors of the National Institute of Mental Health and the National Institute of Drug Abuse, as Council member and President of the American College of Neuropsychopharmacology, as a Member and Chair of the Psychopharmacological Drugs Advisory Committee of the FDA as well as consultant for the Orphan Products Development Review Group, FDA. She is a member of the Advisory Board of the Brain and Behavioral Research Foundation (NARSAD). She is currently the Deputy Editor of the American Journal of Psychiatry and on the editorial board of several other journals in the field. Dr Tamminga was elected to the Institute of Medicine of the National Academies of Sciences in 1998 and has served on several IOM committees in that capacity.
The goal of Dr. Tamminga’s research is to examine and understand the mechanisms underlying schizophrenia, especially its most prominent symptoms, psychosis and memory dysfunction, in order to build rational treatments for the illness. She evaluates the function of the living human brain in individuals with and without schizophrenia, using brain imaging techniques. Then, building on this knowledge, she uses human postmortem brain tissue to translate the functional alterations from the living human patient into molecular observations of the illness. Her ultimate goal is to base novel pharmacologies for psychosis and memory dysfunction on these observations and to use the altered in vivo imaging and postmortem molecular changes as biomarkers and targets for identifying animal models of disease and novel active pharmaceuticals.
Learning objectives:
1. Review criteria for conventional psychosis diagnosis
2. Review biomarkers for psychosis presentations
3. Consider relationships between clinical and biomarkers characteristics of psychosis.
For Physicians: CME credit will be given.
For Psychologists: The Oklahoma State Board of Examiners of Psychologists, the American Psychological Association and the Oklahoma Psychological Association recognizes AMA PRA Category 1 credit™.
For Social Workers: This event has been approved by the Oklahoma State Board of Licensed Social Workers for 1 hour Category 1Clinical. (CEP Number - 20150007)
For LPCs and LMFTs: An application has been made to the State Board of Behavioral Health Licensure (BBHL) for 1 hour of CE.
For CADCs and LADCs: Laureate Psychiatric Clinic and Hospital, Tulsa, Oklahoma, is accredited as a provider of continuing chemical dependency education by the State of Oklahoma - Board of Licensed Alcohol and Drug Counselors for 1 hour of CE.
REGISTER TO ATTEND!
RSS Feed